Apixaban Discontinuation Prior To Major Surgery: Results From A Prospective Single Center Study

Authors

Edwin Lam, Thomas Jefferson UniversityFollow
Luis Eraso, Thomas Jefferson UniversityFollow
Taki Galanis, Thomas Jefferson UniversityFollow
Walter K. Kraft, Thomas Jefferson UniversityFollow
Geoffrey Ouma, Thomas Jefferson UniversityFollow
Lynda Thomson, Thomas Jefferson UniversityFollow
Eugene Viscusi, Thomas Jefferson UniversityFollow
Douglas Stickle, Thomas Jefferson UniversityFollow
Jerald Z. Gong, Thomas Jefferson UniversityFollow
Suzanne Adams, Thomas Jefferson UniversityFollow
Geno Merli, Thomas Jefferson UniversityFollow

Files

Description

Primary Objective

• Estimate the proportion of patients who achieve a plasma apixaban concentration of/mL following at least 48 hours of discontinuation prior to surgery or invasive procedure

Secondary Objective

• Perioperative and follow up arterial or venous thromboembolic events, major bleeding, clinically significant non-major bleeding complications. Correlation of apixaban anti-Factor Xa (FXa) activity and plasma apixaban concentrations at pre-admission and prior to surgery

Publication Date

3-18-2019

Keywords

perioperative anticoagulation, direct acting oral anticoagulant, bleeding

Disciplines

Medical Pharmacology | Medicine and Health Sciences | Surgery

Comments

Presented at the American College of Cardiology’s 68th Annual Scientific Session & Expo in New Orleans, LA

Recommended Citation

Lam, Edwin; Eraso, Luis; Galanis, Taki; Kraft, Walter K.; Ouma, Geoffrey; Thomson, Lynda; Viscusi, Eugene; Stickle, Douglas; Gong, Jerald Z.; Adams, Suzanne; and Merli, Geno, "Apixaban Discontinuation Prior To Major Surgery: Results From A Prospective Single Center Study" (2019). Department of Pharmacology and Experimental Therapeutics Posters. 6.
https://jdc.jefferson.edu/petposters/6